Background Oral direct acting antiviral (DAA) treatments for hepatitis C virus (HCV) have emerged in recent years and show excellent results regarding side effects and clearance of the virus (defined as negative HCV PCR 12 weeks after completion of therapy or SVR12).
Aim To assess response to new DAAs in Northern Ireland according to genotype, presence of cirrhosis, and previous treatment.
Method Treatment outcomes were reviewed for all patients treated with a DAA for chronic HCV in Northern Ireland from March 2015 until July 2016.
Results 105 treatments were given to 104 patients (1 patient treated twice) - 68 males, 41 cirrhotic, and 67 with previous treatment failure. Genotype prevalence is shown in Fig 1. 89 received all oral DAA therapy (44 Abbvie product, 28 Harvoni+/- ribavirin, 15 sofosbuvir/daclatasvir/ribavirin) and 16 received sofosbuvir + Peg interferon + ribavirin. Overall 100 (95%) treatments were successful and achieved SVR 12. Three patients (all cirrhotic genotype 1 with prior treatment failure) stopped treatment (Abbvie) within 3 weeks due to decompensation, one of whom achieved SVR12 with subsequent treatment. 1 patient failed with sof/peg/riba and 1 patient failed to attend for SVR12 check (negative at end of treatment).
Conclusions In our experience, all-oral DAA therapy is highly efficacious provided patients can complete the course. Caution is required with cirrhotic patients even if well compensated before treatment.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.